Novo Nordisk shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of ...
A new study from drugmaker Novo Nordisk found that its weight-loss drug Wegovy can reduce the risk of heart problems in people without diabetes, ...
Novo Nordisk reported a study indicated its diabetes and weight-loss drug, Wegovy, helped reduce risks of heart attack, stroke, or death from cardiovascular ...
By Robin Foster HealthDay Reporter. (HealthDay). MONDAY, Nov. 13, 2023 (Healthday News) -- In a finding that could change the landscape of heart disease ...
Data indicates cardiovascular protective benefits from taking the obesity drug Wegovy. It's unclear if this data will convince payers to change their ...
By Eleanor Laise. Eli Lilly also scores, analysts say, as trial results leave door open for new obesity drug to top Wegovy's benefits.
Novo Nordisk presented showed that its obesity treatment Wegovy can help patients with heart disease, with benefits not due solely to weight loss.
The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.
A clinical trial found it could reduce the risk of heart attack, stroke, or heart-related death in people with cardiovascular disease.
People with heart disease who took the weight loss medicine Wegovy were significantly less likely to have a heart attack or stroke, results of a much ...
The data confirmed a cardiovascular benefit and showed the drug could help pre-diabetic people control their blood sugar. Published Nov. 13, 2023.
New evidence suggests that semaglutide, sold as Ozemipc or Wegovy, could have far-reaching beneficial effects for cardiovascular health and heart failure.